

ARTÍCULO DE MAYOR FACTOR DE IMPACTO MARZO 2015

Miguel Martín, Sibylle Loibl, Gunter von Minckwitz, Serafín Morales, Noelia Martínez, Angel Guerrero, Antonio Anton, Bahriye Aktas, Winfried Schoenegg, Montserrat Muñoz, José Ángel García-Saenz, Miguel Gil, Manuel Ramos, Mireia Margeli, Eva Carrasco, Cornelia Liedtke, Grischa Wachsmann, Keyur Mehta and Juan R. De la Haba-Rodríguez
Phase III Trial Evaluating the Addition of Bevacizumab to Endocrine Therapy As First-Line Treatment for Advanced Breast Cancer: The Letrozole/Fulvestrant and Avastin (LEA) Study.

Journal of clinical oncology: 2015 Mar 20; 33(9):1045-52. doi: 10.1200/JCO.2014.57.2388

FACTOR DE IMPACTO: 17,960

Enlace: <http://jco.ascopubs.org/content/33/9/1045.long>

© 2015 by American Society of Clinical Oncology 

Phase III Trial Evaluating the Addition of Bevacizumab to Endocrine Therapy As First-Line Treatment for Advanced Breast Cancer: The Letrozole/Fulvestrant and Avastin (LEA) Study

Miguel Martín[†], Sibylle Loibl, Gunter von Minckwitz, Serafín Morales, Noelia Martínez, Angel Guerrero, Antonio Anton, Bahriye Aktas, Winfried Schoenegg, Montserrat Muñoz, José Ángel García-Saenz, Miguel Gil, Manuel Ramos, Mireia Margeli, Eva Carrasco, Cornelia Liedtke, Grischa Wachsmann, Keyur Mehta and Juan R. De la Haba-Rodríguez

 Author Affiliations

Corresponding author: Miguel Martín, MD, PhD, Medical Oncology Department, Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense de Madrid, C/ Dr Esquerdo 46, Madrid 28009, Spain; e-mail: mmartin@geicam.org.

Presented, in part, at the 35th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 4-8, 2012; the 37th Biennial Meeting of the European Society of Medical Oncology, Vienna, Austria, September 28-October 2, 2012; and the 17th Biennial Meeting of the European Cancer Congress, Amsterdam, the Netherlands, September 27-October 1, 2013.

M. Martín and S. L. contributed equally to this article.

ONCOLOGY JOURNAL OF CLINICAL ONCOLOGY



Fundación para la Investigación Biomédica del Hospital Clínico San Carlos
Instituto de Investigación Sanitaria San Carlos (IdISSC)
C/Profesor Martín Lagos s/n ES28040 Madrid
Tel.: +34 91 3303793; Fax: +34 91 3303515
E-mail: fuinvest.hcsc@salud.madrid.org